Refine
Year of publication
- 2017 (2) (remove)
Document Type
- Doctoral Thesis (2)
Language
- English (2) (remove)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Arzneimittelrückstand (1)
- Atmosphärendruckplasma (1)
- Depression (1)
- Diclofenac (1)
- Hydroxyl (1)
- Hydroxylradikale (1)
- Ketamin (1)
- Legionella (1)
- Legionellen (1)
- Plasmachemie (1)
Institute
- Institut für Pharmazie (2) (remove)
Pharmaceutical residues are found in increasing concentrations in the environment and in potable water where they have verifiable effects on aquatic life. Conventional methods for water treatment are not able to sufficiently abate these generally stable compounds. It was found that physical plasma generated directly in water can degrade several of these recalcitrant organic pollutants. Studies on the basic plasma chemical processes for the model system of phenol showed that the degradation is primarily caused by hydroxyl radicals. This was confirmed by reaction chemistry and spin trap enhanced electron paramagnetic resonance spectroscopy (EPR). The degradation of diclofenac and its by-products were investigated in detail to perform a first risk-assessment of the new technology. Findings are not limited to the application of plasma but applicable to other advanced oxidation processes (AOP) that are based on the generation of hydroxyl radicals as well. Additionally, pulsed corona plasma and pulsed electric fields were assessed for their capacity to kill Legionella pneumophila in water. Whereas it was possible to kill L. Pneumophila with both methods, plasma treatment resulted in an enhanced bacterial killing. Therefore, advanced oxidation processes (AOP) and plasma treatment in particular are some of the few feasible approaches to decompose recalcitrant compounds in water.
Introduction: Ketamine (KET) is widely used as anaesthetic drug. Beside its pronounced an-aesthetic effects as caused by antagonism of NMDA receptors, ketamine also causes potent analgesia. Moreover, There are ample new evidences, firstly, that 2R,6R/2S,6S-enantiomers of hydroxynorketamine (HNK), exert neuro-modulating effects by AMPA-receptor activation and, secondly, that the plasma levels of norketamine (n-KET) after oral dosing are higher than after intravenous administration. From the physicochemical point of view ketamine is expected to be a substrate of drug transporters. Thus, it was the aim of this study to separate and quantify KET and its metabolites in human serum, urine and feces; investigate the role of transporter proteins in the intestinal absorption, distribution and elimination of ketamine; and evaluate pharmacokinetics and metabolism of a newly developed prolonged-release keta-mine dosage form to confirm its suitability for chronic treatment of CNS-diseases (e.g. de-pression) according to the new “ketamine metabolite paradigm”. Materials and methods: Quantification of ketamine was done by a LC-MS/MS-based quantifi-cation method on the QTRAP4000 instrument. Samples were extracted by methyl tert-butyl ether after addition of sodium carbonate to liberate the free base; Single transfected MDCKII cells overexpressing OCT1, OCT2, OCT3, and MATE1 or MATE2K, and HEK293 cells over-expressing OATP2B1 were used to study the cellular uptake of ketamine. Inside-out lipovesi-cles were used to determine the affinity of ketamine to the efflux transporter P-glycoprotein (P-gp). Uptake into cells or vesicles was determined by liquid scintillation counting. Func-tionality of all in vitro systems was assured by using in each case appropriate probe sub-strates; The dose-escalation study was performed in five consecutive periods (7 days wash-out) in 15 healthy subjects (5 females and 10 males. 20-35 years, BMI 19.4-27.6 kg/m2). Results: We introduce for the first time the separation and quantification of the active me-tabolites 2R,6R/2S,6S-HNK; Ketamine was shown to be taken up significantly in a time- and concentration-dependent manner by OCT1-3. The affinity to OCT transporters at pH=6.5 was several fold higher than that at pH=7.4. ), ketamine showed a significant but low affinity to P-gp. In contrast to this, we could not detect any transport of ketamine by MATE1 / 2K or OACPT2B1; and PR-KET was safe and well tolerated with higher metabolites productivity, different pharmacokinetic properties and longer T1/2 when compared to IV-KET or IR-KET. Conclusion: the uptake transporters OCT1 & 3 and the efflux transporter P-gp may play a role in the intestinal absorption of the drug. On the other side, P-gp, MATE1 / 2K and OCT are not expected to contribute significantly to tissue (brain) distribution or renal excretion of ketamine; Moreover, the prolonged-release ketamine undergoes dose-dependent “first-pass” metabolism which generates substantially increased plasma exposure of downstream me-tabolites with potential neuro-modulating effects compared to ketamine after intravenous administration.